BH
IBO

Burk Holdings’s Impact BioMedical IBO Stock Holding History

Burk Holdings’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16 Buy
+27
New +$13 ﹤0.01% 676

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $516M AUM 19.85% 1-Year Est. Return

Burk Holdings's IBO Position: Q1 2026 in Review

Burk Holdings opened a new position in Impact BioMedical (IBO) in Q1 2026: 27 shares worth $16. The stake represents ﹤0.01% of the portfolio and ranks #676 among its holdings.

20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Burk Holdings held 27 shares of Impact BioMedical worth $16 as of Q1 2026.
  • Impact BioMedical was a new Burk Holdings position in Q1 2026.
  • Impact BioMedical made up ﹤0.01% of Burk Holdings's portfolio in Q1 2026, its #676 holding.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Burk Holdings's 13F filing for Q1 2026, filed 8 May 2026.